Avalyn raises $175M to test inhaler versions of IPF medicines in PhII trials
Avalyn Pharma announced Wednesday that it closed a $175 million Series C round, which it plans to put toward two Phase II studies of inhaled …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
